LMTX drug shows promise for use in Parkinson’s disease therapy

Preclinical results from TauRx Therapeutics Ltd (Aberdeen, Scotland) have indicated that LMTM, the active agent in its LMTX® drug originally developed for Alzheimer’s disease (AD) treatment, may also be beneficial as a Parkinson’s disease (PD) medication.

To view restricted content, please:

Register FREE

Login

alpha-synuclein Alzheimer's disease drug development Parkinson's disease